Hospital Pharmacy Europe - Rheumatology,

Click here

Saturday 18 May 2013 Register Login

You are here:

Suppliers Guide

New neurology product

Hospital Pharmacy Europe is assisting with a survey on messaging for a new neurology product. Click here

LATEST ISSUE

Contamination control and preparation of anticancer drugs, medicines reconciliation, Ruconest drug evaluation, ivacaftor for cystic fibrosis , oxycodone-naloxone prolonged-release tablets, IV chemotherapy, capsaicin in the treatment of severe neuropathic pain, alitretinoin in severe chronic hand eczema, Zyclara for actinic keratoses

Pharmacy Zone: Rheumatology

Magazine	Sponsored content
News	Video

Page:

1

Mon 8 Apr

SMC recommends abatacept
The Scottish Medicines Consortium (SMC) has announced today that abatacept (Orencia®) has been accepted for use within NHS...

Wed 3 Apr

Humira approved for JIA
AbbVie (NYSE: ABBV) has announced that the European Commission (EC) has approved an extension of the EC marketing authorisation...

Tue 12 Mar

Abatacept positive guidance from NICE
The National Institute for Health and Clinical Excellence (NICE) has announced today that it recommends the use of abatacept in...

Mon 4 Mar

EU approval for Ilaris®
Novartis has announced that the European Commission (EC) has approved llaris (canakinumab, ACZ885) in the treatment of patients...

Wed 13 Feb

Ablynx's anti-IL-6R Nnanobody shows excellent 24 week safety and efficacy results
Ablynx (Euronext Brussels: ABLX) has announced efficacy and safety data for its anti-IL-6R Nanobody, ALX-0061, at the 24 week...

Thu 24 Jan

Positive CHMP opinion for Ilaris®
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...

Fri 5 Oct
2012

Subcutaneous formulation of ORENCIA® approved by European Commission
Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous...

Wed 25 Jul
2012

Cost effectiveness of TNF-alpha inhibitors in RA
A number of biologic drugs for the treatment of rheumatoid arthritis are now available, and real life observational studies can...

Mon 9 Jul
2012

EULAR: Canakinumab 'option for severe childhood arthritis'
A Phase III study of the investigational drug canakinumab meets primary endpoint

Fri 11 May
2012

Pfizer's new RA drug backed for FDA approval
The Janus Kinase (JAK)-3 inhibitor is hoped to replace Humira as the first-choice RA drug

Mon 30 Apr
2012

NICE turns down Benlysta on grounds of cost
Final draft guidance stage from the UK drug recommendation body turns down Benylsta for SLE

Mon 16 Apr
2012

Certolizumab pegol shows AxSpaA efficacy in Phase III
UCB announced good top-line Phase 3 for certolizumab pegol in adult-onset active axial sponylarthritis

Wed 4 Apr
2012

Naproxcinold, OA application discussed with FDA
NicOx discussed a proposed New Drug Application for treatment of osteoarthritis signs and symptoms

Tue 20 Mar
2012

Protelos, Osseor PI needs update, says CHMP
The medicines remain important osteoporosis treatments but PI changes are needed, says CHMP

Mon 19 Mar
2012

Generic positive opinions for EU released
The CHMP adopted a positive opinion on docetaxel and zoledronic acid in its March 2012 meeting

Fri 17 Feb
2012

Cimzia to seek approval for active PA in 2012
Extension sought for extension of moderate-to-severe to active psoriatic arthritis, EU approval, within 2012

Tue 31 Jan
2012

T-cell targeting medication may relieve psoriatic arthritis
Early, aggressive treatment may help reduce symptoms and improve joint function

Fri 11 Nov
2011

Cimzia® 'provides rapid arthritis response'
Certolizumab pegol 'improves disease activity and physical function up to 28 weeks', conference told

Thu 10 Nov
2011

BICLA hailed as 'meaningful measure of SLE'
Epratuzumab phase IIb data demonstrates sensitivity of novel BILAG-based composite endpoint, conference told

Thu 10 Nov
2011

Canakinumab shows efficacy for juvenile arthritis
Drug substantially reduces steroid use in 45% of patients with childhood arthritis, conference told

Page:

1

Web design, hosting and programming by ModeZero